A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report.
Antiviral Agents
/ therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections
/ complications
Critical Care
Drug Combinations
Extracorporeal Membrane Oxygenation
Humans
Infection Control
Japan
Lopinavir
/ therapeutic use
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
Respiration, Artificial
Ritonavir
/ therapeutic use
SARS-CoV-2
Coronavirus disease 2019 (COVID-19)
Extracorporeal membrane oxygenation (ECMO)
Infection control
Intensive care
Lopinavir/ritonavir
Respiratory failure
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
17
03
2020
revised:
25
03
2020
accepted:
29
03
2020
pubmed:
23
4
2020
medline:
17
6
2020
entrez:
23
4
2020
Statut:
ppublish
Résumé
An ongoing outbreak of a novel coronavirus disease (coronavirus disease 2019, COVID-19) has become a global threat. While clinical reports from China to date demonstrate that the majority of cases remain relatively mild and recover with supportive care, it is also crucial to be well prepared for severe cases warranting intensive care. Initiating appropriate infection control measures may not always be achievable in primary care or in acute-care settings. A 45-year-old man was admitted to the intensive care unit due to severe pneumonia, later confirmed as COVID-19. His initial evaluation in the resuscitation room and treatments in the intensive care unit was performed under droplet and contact precaution with additional airborne protection using the N95 respirator mask. He was successfully treated in the intensive care unit with mechanical ventilation and extracorporeal membrane oxygenation for respiratory support; and antiretroviral treatment with lopinavir/ritonavir. His total intensive care unit stay was 15 days and was discharged on hospital day 24. Strict infection control precautions are not always an easy task, especially under urgent care in an intensive care unit. However, severe cases of COVID-19 pneumonia, or another novel infectious disease, could present at any moment and would be a continuing challenge to pursue appropriate measures. We need to be well prepared to secure healthcare workers from exposure to infectious diseases and nosocomial spread, as well as to provide necessary intensive care.
Identifiants
pubmed: 32317225
pii: S1341-321X(20)30112-4
doi: 10.1016/j.jiac.2020.03.018
pmc: PMC7166031
pii:
doi:
Substances chimiques
Antiviral Agents
0
Drug Combinations
0
lopinavir-ritonavir drug combination
0
Lopinavir
2494G1JF75
Ritonavir
O3J8G9O825
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
756-761Informations de copyright
Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Intensive Care Med. 2020 Apr;46(4):576-578
pubmed: 32077996
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Korean Med Sci. 2020 Feb 17;35(6):e79
pubmed: 32056407
JAMA. 2020 Apr 7;323(13):1245-1246
pubmed: 32074258
Intensive Care Med. 2020 Feb;46(2):357-360
pubmed: 32025779
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Intensive Care Med. 2020 Apr;46(4):579-582
pubmed: 32103284